Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 31, 2026. The filing serves to disseminate a press release containing financial information for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) but are not detailed in the body of this Form 8-K.
Material Changes
No material changes versus prior periods are described in the text of this filing. The document solely references the issuance of the fiscal year 2025 financial results.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, management commentary, risks, or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual financial figures for the fiscal year ended December 31, 2025.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol (CVKD) and exchange (Nasdaq Capital Market) for current market data.
- Note that the financial data in this 8-K is not incorporated by reference into future filings.